Latest Truscreen (Asx:Tru) News

TruScreen Group Limited reported a 17% decline in first half FY2026 product sales but affirmed full-year revenue guidance at NZ$2.8 million, supported by strategic expansions and a successful NZ$4 million capital raise.

TruScreen Group Limited has announced a placement of over 1.7 million shares to settle marketing invoices and provide an equity incentive to its CFO, signaling strategic capital management ahead of its next growth phase.

TruScreen Group Limited has corrected an administrative error in its Share Purchase Plan allocations, ensuring shareholders receive their proper pro-rata entitlements ahead of a key special meeting.

TruScreen Group Limited has successfully raised NZ$2.35 million through a share placement, attracting new institutional investors from Asia, while launching a discounted share purchase plan for existing shareholders.

TruScreen Limited has obtained a waiver from NZ RegCo allowing it to allot oversubscribed shares up to 10 business days after its capital raising offer closes, subject to shareholder approval. This move aims to streamline the company’s NZ$3 million placement and share purchase plan.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Ordinary Shares Group Limited has announced a combined share purchase plan and placement to raise approximately NZD 1.78 million, aiming to accelerate its international expansion and cervical cancer screening initiatives.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited forecasts a robust 64% increase in FY26 sales, driven by strategic market expansions and new distribution agreements. The company’s AI-enabled cervical cancer screening technology is gaining traction across emerging markets.

TruScreen Group Limited has announced a NZ$3 million capital raise to fund strategic growth initiatives across Asia and Africa, alongside repaying existing debt. The raise includes a placement and share purchase plan with free attaching options, signaling confidence in its expanding cervical cancer screening programs.

TruScreen Group Ltd reports a dip in FY25 sales but forecasts a robust rebound in FY26 driven by resumed programs and expansion in key emerging markets. Strategic partnerships and AI-enabled technology underpin its growth ambitions.

TruScreen Group Limited reported a 19% revenue decline in FY2025 due to delayed rollouts in key emerging markets but anticipates a strong rebound with FY2026 sales forecast to exceed NZ$2.8 million.